Interviews

Biosimilar Misconceptions, PBM Transparency, and Value-Based Care: Insights From Canavan & O'Dell

June 15th 2025

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain the misconception that cheaper biosimilars automatically lead to lower costs due to pharmacy benefit manager (PBM) spread pricing, while also highlighting major PBM trends toward increased transparency, value-based care, and efforts to reduce prescription costs.

Automatic Biosimilar Substitution and Patient Education Advocated by Elena Wolff-Holz, MD

May 26th 2025

Video

Elena Wolff-Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications.

Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD

May 11th 2025

Video

Elena Wolff-Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to lower costs, and a possible lower immunogenicity profile.

The Global Biosimilar Development and Approval of Yesintek With Elena Wolff-Holz, MD

April 13th 2025

Video

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety data while noting challenges in global patient recruitment and regulatory navigation.

PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing

March 30th 2025

Article

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.

How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

March 9th 2025

Podcast

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?

Enhancing Biosimilar Adoption in Value-Based Oncology Care

February 16th 2025

Video

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.

Understanding Biosimilars Through Education and PBM Formulary Perspective

February 2nd 2025

Video

Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) add medications, including biosimilars, to their formularies.

Reducing Financial Toxicity in GI Cancer Care Through Biosimilars

January 5th 2025

Video

Tiago Biachi, MD, PhD, emphasizes that biosimilars are vital for reducing financial toxicity and ensuring equitable, affordable access to advanced treatments in gastrointestinal (GI) cancer care, while calling for dynamic policies and greater cost awareness among clinicians.

How Vertical Integration Drives Innovation and Access in Biosimilars

December 27th 2024

Article

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.